{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(2)"],"submitter":["Cui S"],"pubmed_abstract":["Capture-based next-generation sequencing (NGS) is a potentially useful diagnostic method to measure tumor tissue DNA in blood as it can identify concordant mutations between cell-free DNA (cfDNA) and primary tumor DNA in lung cancer patients. In this study, the sensitivity, specificity and accuracy of capture-based NGS for detecting ALK fusion in plasma cfDNA was assessed. 24 patients with tissue ALK-positivity and 15 who did not harbor ALK fusion were enrolled. 13 ALK-positive samples were identified by capture-based NGS among the 24 samples with tissue ALK-positivity. In addition to EML4-ALK, 2 rare fusion types (FAM179A-ALK and COL25A1-ALK) were also identified. The overall sensitivity, specificity and accuracy for all cases were 54.2%, 100% and 71.8%, respectively. For patients without"],"journal":["Oncotarget"],"pagination":["2771-2780"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5356840"],"repository":["biostudies-literature"],"pubmed_title":["Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer."],"pmcid":["PMC5356840"],"pubmed_authors":["Zhang W","Xiong L","Jiang L","Chu T","Pan F","Wang H","Cui S","Zhao Y","Niu Y"],"additional_accession":[]},"is_claimable":false,"name":"Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.","description":"Capture-based next-generation sequencing (NGS) is a potentially useful diagnostic method to measure tumor tissue DNA in blood as it can identify concordant mutations between cell-free DNA (cfDNA) and primary tumor DNA in lung cancer patients. In this study, the sensitivity, specificity and accuracy of capture-based NGS for detecting ALK fusion in plasma cfDNA was assessed. 24 patients with tissue ALK-positivity and 15 who did not harbor ALK fusion were enrolled. 13 ALK-positive samples were identified by capture-based NGS among the 24 samples with tissue ALK-positivity. In addition to EML4-ALK, 2 rare fusion types (FAM179A-ALK and COL25A1-ALK) were also identified. The overall sensitivity, specificity and accuracy for all cases were 54.2%, 100% and 71.8%, respectively. For patients without","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jan","modification":"2025-04-04T14:33:24.564Z","creation":"2019-03-26T23:46:30Z"},"accession":"S-EPMC5356840","cross_references":{"pubmed":["27926526"],"doi":["10.18632/oncotarget.13741"]}}